Oral Muscle peptide ingredient, PeptiStrong® delivers 20% strength gain and 1% increase bone density in latest clinical trial in 56 days

Connecticut, USA (March 6th, 2024) – Nuritas, a global leader in AI-based peptide discovery from natural plant sources announces the results from the latest clinical trial for PeptiStrong®, showing positive results on strength, bone density and muscular endurance in a male and female population.

PeptiStrong® – An AI discovered ingredient for muscle health created as a hydrolysate from fava bean protein, has self-affirmed GRAS status and is Health Canada-approved, has now successfully undergone three clinical studies.

In the latest trial, males and females aged 19 – 40 years were given either a daily dose of 2.4g of PeptiStrong® or placebo for 56 days. At day 28 and 56, upper and lower body strength, body composition and muscular endurance was measured. PeptiStrong® was found to increase strength by 19.7% compared to placebo, this increase was also gained faster than placebo. Interestingly, there was a significant increase in endurance after just 4 weeks. In addition, a 1% increase in overall bone density was seen adding to the versatility of this multi – peptide ingredient.

“These new trial results, add significant value to PeptiStrong®, not only do we continue to see positive outcome in strength, but we also see a benefit in strength recovery for women and an overall increase in bone density,” said Dr Andy Franklyn-Miller, Chief Medical and Innovation Officer, Nuritas. “Peptistrong was designed not only for supplements, but the food market, to add health benefits to everyday staples such as cereals, pasta, bread and baked goods”.

Previously, PeptiStrong® was shown to be four times more effective than milk protein in improving lean muscle protein synthesis and helped recovery of muscle mass after immobilization. In a second trial, PeptiStrong® significantly increased performance and strength recovery, it reduced muscular fatigue and helped promote muscle repair after exercised induced muscle damage.

“Muscle strength is about so much more than athletic performance, it has been shown in meta-analysis to reduce all-cause mortality by 17% reducing cardiovascular and metabolic disease, neurological and total cancers.” Added Dr Nora Khaldi, Founder and CEO, Nuritas. “These amazing new results show us that PeptiStrong® can have much wider applications in health, and we see a 1% increase in bone density after only 56 days, which gives a new effective option for peri and post menopausal women.

“We have an impressive pipeline of new ingredients joining the portfolio later in the -2024 including a PeptiControl, improving metabolic glucose control, and reducing post eating fatigue and increasing fullness after eating and PeptiSleep, focused on cortisol lowering and reducing the time taken to get to sleep and sleep quality, both of these ingredients are out at clinical trial as we speak” concluded Dr Franklyn-Miller, “It’s an exciting time for Nuritas”.

About Nuritas
Nuritas empowers people to optimize their health and well-being by unlocking the untapped potential of clinically tested and proven peptide ingredients across health, wellness, nutrition, and personal care. Nuritas is the preferred innovation partner of choice for agile manufacturers seeking to create at an accelerated rate a brand-new category of products that enhance consumer vitality. The limitless potential of Nuritas’ cutting-edge, AI-based technology coupled with the superpowers of nature offer healthier, safer, environmentally sustainable, and more efficacious ingredients. Nuritas’ commitment lies in helping brands fortify consumer vitality while mitigating and protecting against the adverse impacts of modern living. Find us on Twitter, LinkedIn or via our website at www.nuritas.com.